BRIC-Translational Health Science and Technology Institute

(An institute of the Biotechnology Research and Innovation Council,
Department of Biotechnology, Ministry of Science and Technology, Govt. of India)

Request for Proposal (RFP)
(Through Government e-Marketplace)

FOR

Optimization of technology for production of Hepatitis E virus-like particle (HEVLP) in 5–10 L scale bioreactor and supply of approximately 10 mg of 90% or more purified HEVLP protein.

'RFP' document can be downloaded from following websites:
https://bidplus.gem.gov.in/all-bids

(RFP No: THSTI/S&P/RFP/06/25-26)
Dated: 10th December 2025

REQUEST FOR PROPOSAL

Subject: Request for Proposal for Optimization of technology for production of Hepatitis E virus-like particle (HEVLP) in 5–10 L scale bioreactor and supply of approximately 10 mg of 90% or more purified HEVLP protein.

BRIC-Translational Health Science and Technology Institute (THSTI) Faridabad (herein after referred as **'the institute'**) is an institute of the Biotechnology Research and Innovation Council, Department of Biotechnology, Ministry of Science and Technology, Government of India.

The Executive Director of BRIC-THSTI invites Request for Proposal (RFP) from shortlisted agencies/firms that meet the eligibility criteria as outlined in the EOI document (THSTI/S&P/REOI/04/25-26 dated 15th October 2025).

Schedule for the Request for Proposal

Date of issue	:	10th Dec,2025 at 1600 Hrs.
Last date and time for submission of Proposal by the Bidders	:	31st Dec ,2025 at 1600 Hrs.
Date and time of opening of the Proposals	:	31st Dec,2025 at 16:30 Hrs.
Estimated value of works	:	141.60 Lakhs (approx.)
Performance security	:	5% of work order value as Bank Guarantee to be deposited on being awarded the work
Validity of the Proposal in response to RFP	:	120 days from the date of opening

Note:

i. In case, the last date of receipt of RFPs and/or the day of opening of RFPs is declared as a Public Holiday or there is non- functioning of the institute due to any unavoidable reason, the next working day will be treated as the last date of receipt of RFPs and/or the day of opening of RFPs. The time will remain the same. No separate intimation will be given in this connection.

ii. Kindly note that online submission of RFP through GeM portal will be considered against this RFP. Requests for extension of date and time for submission will not be

entertained. The Executive Director, THSTI reserves the right to accept/ reject any or all RFP either in part or in full without assigning any reasons thereof.

iii. In case of any clarification with regard to submission of RFPs, please contact to Sh. Manoj Kumar, Section Officer (S&P) (Tel: 0129-2876300/437) manoj.kumar@thsti.res.in and purchase@thsti.res.in.

Sd/-
AO (S&P)
THSTI, Faridabad

INDEX

Contents `

1. Background:

BRIC-THSTI has demonstrated the immunogenicity and potent virus neutralization potential of His-tagged HEVLP, generated in *E.coli* expressing a truncated version of the viral ORF2 protein. We have generated a construct encoding the tag-free version of the truncated viral ORF2 protein and confirmed expression of the ORF2 protein by Coomassie staining and western blot analysis using the corresponding antibody. The current proposal aims at using the same clone to scale up tag-free VLP production in Bioreactor, followed by its purification and characterization.

2. Purpose:

BRIC-THSTI desires to generate optimized technology for production of Hepatitis E virus-like particle (HEVLP) in 5–10 L scale bioreactor and evaluate its efficiency as a vaccine against the HEV. The company should provide the master cell bank, details of upstream and downstream process development and characterization of the end product and approximately 10mg of 90% or more purified HEVLP protein for characterization and functional validation at BRIC-THSTI.

3. Scope of work:

a) Upstream process should be optimized in 5–10 L scale in a bioreactor.
b) Downstream process should focus on maximizing the yield of VLP, with 90% or more purity, while retaining the characteristic to induce neutralizing antibody production against HEV.
c) Protein purity, identity and characteristics should be confirmed by mass spectrometry, Coomassie brilliant blue staining, silver staining, ELISA, western blot analysis (in house developed and characterized anti-ORF2 antibody will be provided if necessary), CD, UV spectroscopy and differential scanning calorimetry.
d) VLP should be characterized by Transmission electron microscopy, Dynamic light scattering (DLS), gel filtration chromatography and ultra centrifugation.
e) Functionality to be confirmed by measuring the ability of the purified protein to to induce neutralizing antibody production against HEV (Immunization experiment and neutralization assay may be done by the PI at THSTI if requested).
f) Quality assurance by checking the following parameters: Mycoplasma, Endotoxin, HCP, HCD, Mtb etc.
g) Stability of the purified protein should be tested as per the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use guideline. Real time accelerated and stress stability studies for up to 6 months.

4. Role of the Institute & Bidder:

a. Role of BRIC THSTI:

BRIC-THSTI shall provide the clone and initial expression data. If necessary anti-ORF2 antibody will be provided for confirming protein expression. Virus neutralization assay for evaluating the functional attribute of the purified antigen will be carried out

at BRIC-THSTI. BRIC-THSTI will not provide the know-how of assays related to evaluation of the vaccine candidate. Bidder may develop their own assays or request BRIC-THSTI to perform the assays.

b. Role of bidder/company:

i. The company shall develop the upstream and downstream process for protein expression and purification and provide the required amount of purified protein as per the technical specifications provided in section 4.
ii. The Company shall have the required infrastructure, technical know-how, experience and regulatory understanding for executing the work.
iii. Rights of the upstream and downstream process as well as the master cell bank should be transferred to BRIC-THSTI.

5. **Joint Monitoring Committee:** A Bidder-THSTI Joint Monitoring Committee may be established to monitor progress of the work vis-a-vis timelines, quality of work, decisions to be taken during course of project, etc.

6. **Intellectual Property Rights (IPR) & Licensing:**

In case of transfer of Technology, BRIC-THSTI is the sole owner of the said Technology, including any underlying Intellectual Property(ies) and commercialization rights. Intellectual Property (IP) shall mean patents, rights to inventions, copyright and related rights, moral rights, rights in designs, rights in trademarks, rights to preserve the confidentiality of information (including know-how and trade secrets) and any other intellectual property rights, in each case whether registered or unregistered and including all applications (or rights to apply for and be granted), divisional, continuations, continuations-in-part, reissues, renewals or extensions of, and rights to claim priority from, such rights and all similar or equivalent rights or forms of protection which subsist or will subsist now or in the future in any part of the world regarding subject matter disclosed in Licensed patents. BRIC-THSTI is lawfully entitled to enter into any form of non-exclusive License Agreements with selected companies including transfer of the Technology through suitable Agreement(s). In case of Joint development of the Product, Background Intellectual Property ("BGIP") shall always remain the sole and Non-exclusive property of the Party generating the BGIP. Any IP that is newly conceived and reduced to practice during the collaboration, excluding any improvements made solely to a Party's BGIP, shall be jointly owned by BRIC-THSTI and the Company. Any improvements to a Party's own BGIP shall remain the sole property of that Party. All such provisions related to intellectual property rights shall be governed by the Department of Biotechnology (DBT) IP Policy, as revised and approved by DBT.

a) Process involved in Partnership/Collaboration:
Interested companies will be shortlisted based on their facilities and capabilities. On shortlisting of technically suitable companies, one Request for Proposal (RFP) will be shared with the shortlisted candidates. At the RFP stages, technically suitable candidates will be required to provide complete technical

details along with their financial proposal. Qualified companies/manufacturers will only be contacted for execution of Agreement for collaboration.

b) Publication:
THSTI would reserve the sole right to publish or not publish the work proposed here either in parts or in its entirety. If, however it gets published, THSTI would reserve the sole right to either include or not include authors from outside the organisation.

c) Data Rights: Data rights shall be solely owned by BRIC-THSTI.

7. Timeline for completion of the project:

a) The entire work should be completed within 12 months of releasing the work order, as per the following timeline:
   i. Pilot scale optimization of the production pipeline and demonstration of neutralization potential of the antibody induced by the purified protein antigen. Duration: 4 months.
   ii. 3-5 consistency batch data generation and completion of characterization. Duration: 4 months.
   iii. Stability data generation and detailed technical report submission. Duration: 4 months.

b) The entire documentation and testing reports should be submitted within the project duration.
c) Technology transfer and demonstration of the technology to users in THSTI also to be provided within the project duration.
d) Final acceptance certificate will be issued by THSTI only after completing point (i), (ii) & (iii) mentioned above.

8. Financial bid: The financial bid should be submitted as per the format at **Annexure-II.** Under no circumstances, there will be any change in the price quoted in the financial bid. No escalation in total cost shall be accepted, and any such variations have to be borne by the bidder.

9. Authorized Signatory: The 'Applicant' mentioned in the RFP document shall mean the one who has signed the Proposal document forms. The applicant should be the Head of the laboratory/institution/organization or a duly Authorized Representative, for which a Certificate of Authority shall be submitted. All certificates and documents (including any clarifications sought and any subsequent correspondence) submitted thereby, as far as possible, shall be furnished and signed by the Authorized Representative.

10. Documents to accompany the proposal: The complete proposal shall be submitted in "two bid system" in two parts viz. Technical proposal and Financial Bid as detailed below:

a) **Part-1:**
   i. Technical proposal as per Annexure-I

ii. RFP document duly signed on all pages

b) **Part-2:** - Financial bid as per Annexure-II

No pricing information, neither for any individual module nor total, should be mentioned in the technical proposal (Part 1) of the bid. Mentioning financial information in the technical proposal may be grounds for rejection of the bid.

11. Bid Evaluation Criteria/ Methodology for Selection:

Selection of the Bidder will be based on Least Cost method (L-1) based on the following criteria: -

a) Technical Proposal Evaluation Criteria:-

S. No.	Evaluation criteria	Max Score
1	**Experience and capabilities (50 marks)**	
1.1	a) Prior experience in protein expression and purification using Bioreactor technology (recombinant protein/VLP). Full marks if >5 products (recombinant protein/VLP) developed and handed over to client or used in the clinic in last 3 years (if justified with adequate documentary evidence / supporting information).	20
1.2	Team quality: Qualifications, experience and achievements of the scientific team handling the project. Full marks if a) Lead scientist (fully involved operationally, CV to be included in the proposal) has at least 10 years' experience in similar product (recombinant protein/VLP) development. b) Team consists of members with minimum 2 years' experience in similar product development.	20
1.3	Analytical technology available in house for protein characterization.	10
	Total	**50**

2	**Work Plan (50 marks)**	
2.1	Adequate financial ability and resource readiness for immediate and timely execution of the work.	20
2.2	Overall description of the project approach. Overall approach taken for the project – judged on team capability, lab facilities and technology, description of methodology, alignment with standard industry norms, logical sequencing of activities, project management and governance. This will be evaluated based on presentation and written proposal.	20

2.3	Titre expected based on past achievements. Full marks if proposal indicates expected > 8g/L at the bioreactor level based on past experience.	10
	Total	**50**
	Grand Total (1+2)	**100**

Note:-

I. Minimum marks required for seller to qualify in technical evaluation is 40.
II. In case the bidder does not meet the criteria to obtain full marks, partial marking will be awarded based on an appropriate method by the internal evaluation team.

b) Financial Bid Evaluation Criteria: Least Cost method (L-1).

12. Rejection of Proposal: The Proposal is liable to be rejected if:

a) The proposal is not submitted as per the requirements indicated in the RFP.
b) Including the finance bid in the technical proposal.
c) Proposal/bid not in the prescribed format.
d) Not properly stamped and signed as per requirements.
e) Received after the expiry of due date and time.
f) Applications not fulfilling the terms of the document.
g) Any other non-compliance.

13. Commercial Terms: Payment to the bidder would be subject to the completion of milestones as stated in RFP documents which may be tentatively stated as follows.

a) Pilot scale optimization of the production pipeline and demonstration of neutralization potential of the antibody induced by the purified protein antigen. Duration: 6 months. Payment of 50% of the total service cost.
b) 3-5 consistency batch data generation and completion of characterization. Duration: 6 months. Payment of 30% of the total service cost.
c) Stability data generation detailed technical report submission. Duration: 3 months. Payment of 20% of the total service cost.

14. Funding Contingency and Stage-wise Execution of Work:

a) The work under this contract shall be executed in a stage-wise manner as per the approved project plan comprising stages (a), (b), and (c). In addition to the issuance of the main Work Order, the Institute shall issue separate **Work Start Confirmations** for each stage, depending upon the progress of the project, specific technical requirements, satisfactory completion of the preceding stage, and the availability of funds
b) The commencement of work for each subsequent stage shall be strictly subject to: Satisfactory completion and acceptance of deliverables of the preceding stage by the Institute, and written authorization issued by the Institute in the form of a Work Start Confirmation.

c) In the event that the funds for the subsequent project year(s) (i.e., 2nd year and/or 3rd year) are not available for any reason whatsoever— including administrative delays, budgetary constraints, or withdrawal/modification of the project sanction — the awarded work shall be deemed to be **automatically pre-terminated** upon completion of the portion corresponding to the funds already released and utilized.
d) Upon such pre-termination, the contractor/vendor shall be entitled only to payment for the work duly completed, verified, and accepted by the Institute. No claim for compensation, damages, loss of profit, or any other consequential or financial liability shall be entertained or payable by the Institute beyond this limit.
e) The vendor shall ensure that no financial or contractual commitments are made in anticipation of subsequent-year funding without receiving written confirmation from the Institute. Any such commitments made at the vendor's discretion shall be entirely at their own risk and cost.
f) The Institute's obligation under this contract shall, in all circumstances, be limited to the start confirmation for the specific project activities covered under this tender.

15. Work Defects, Delay, Penalty and Termination:

a) Any delay in the project timeline must be communicated immediately, and justified. If the project is delayed due to controllable factors and without satisfactory justification, the institute reserves the right to impose a penalty as below:
    i. No penalty for delay up to 50% duration of the project as quoted (eg. 3 months if quoted duration is 6 months).
    ii. Delay beyond 50% of the quoted duration, 1% of the project cost per week of delay beyond 50% duration of the project, up to a maximum of 10% of the value of the project
    iii. In case of delay more than 50% of the quoted duration up to any intermediate stage of the project, the institute reserves the right to levy penalty at Rs. 1,00,000 or 1% of the value of the project till that module (whichever is higher) per week of delay beyond 50% of the quoted time till that module, up to a maximum of 10% of the value of the work done till then, and terminate the contract.
b) Notwithstanding anything elsewhere provided herein and in addition to any other right or remedy available to the institute under the contract or otherwise including right of the institute to claim compensation for delay, the institute may, without prejudice to its right against Bidder in respect of any delay, bad workmanship or otherwise or to any claims for damage in respect of any breaches of the contract and without prejudice to any rights or remedies under any of the provisions of this contract or otherwise and whether the date for completion has or has not elapsed by intimation in writing, absolutely determine the Contract.
c) Default or failure by the Bidder in any of the under mentioned cases, including but not limited to the following shall be the basis of taking action under this clause of the RFP which may include termination:
    i. Failure to provide at the job site, sufficient manpower, material, equipment, machinery, and / or facilities, required for the proper and / or due execution of the work or any part thereof.
    ii. Failure to execute the works or any of them in accordance with the contract.
    iii. Disobedience of any order or instruction of the project in-charge.

iv. Negligence in carrying out the work or carrying out of work found to be unsatisfactory by the Project-in-charge/the institute.
v. Abandonment of the works or any part thereof.
vi. If the Bidder is incapable of carrying out the work.
vii. If the Bidder misconducts in any manner.
viii. If there is any change in the constitution of the Bidder or in the circumstances or organization of the Bidder, which is detrimental to the interests of the institute.
ix. Dissolution of the Bidder (If a firm or commencement of liquidation) or winding up (whether voluntary or compulsory) of the Bidder (if a company or appointment of a receiver or Manager of any of the Bidder's assets and / or insolvency or the Bidder (if a sole proprietorship) or of any partner of the Bidder (if a firm).
x. Distress, execution, or other legal process being levied on or upon any of the Bidders goods and /or assets.
xi. If the Bidder or any person employed by him shall make or offer for any purpose connected with the contract any gift, gratuity, royalty, commission, gratification or other inducement (whether money or in any other form) to any employee or agent to the institute.

d) Any rework required due to error or technical decision of the Bidder will be at the Bidder's own expense
e) In case of any regulatory deficiency, such as use of animal serum, undocumented expression components, lack of appropriate data generation for monoclonality, etc., the institute is entitled to ask for repetition of the affected work at no additional cost or to cancel the contract.
f) In case of any cancellation due to delay or deficiency on technical or regulatory considerations, the institute is only liable to pay for completed modules which are utilizable and unaffected by the technical or regulatory deficiency. Any partly executed modules will not be paid, and completed modules which are not utilizable due to the said deficiency will not be paid.
g) The institute reserves the right to terminate the project without assigning cause. In this case, the institute will pay for all completed modules as well as any work carried out till date, as well as pay for all raw materials and consumables procured for the project or non-cancellable orders placed.
h) The decision of the Executive Director, THSTI as to whether any of the events/ contingencies mentioned in aforesaid clauses entitling the institute to terminate the contract has occurred shall be final and binding upon the Bidder. The reason for the termination stated in the notice of termination shall be final and binding upon the Bidder and shall be non-arbitral. The jobs left, however, by the Bidder shall be got done at his risk and cost through the other agencies and the Contract shall be determined accordingly.

16. General Conditions:

a) **Liability / Accident:** The Bidder shall indemnify and keep indemnified the institute against all losses and claims for injuries and damages to any person or property whatsoever which may arise out of or in consequence of the work and against all claims,

demands, proceedings, damages, costs, changes, expenses whatsoever in respect thereof in relation thereto.

b) **Extra Item:** Any unforeseen item of work/supply as being authorised by the institute and not included in the RFP, shall be done by the Bidder at mutually agreed rates. Written prior approval of the institute should be obtained before undertaking any extra work. Payment of such items shall be made at actual supported by necessary documentary evidence duly approved. No price escalation will be paid for the existing scope of work as specified in the RFP.

c) **Force majeure:** The right of the Bidder to proceed with the work shall not be terminated because of any delay in the completion of the work due to unforeseeable causes beyond the control and without the fault or negligence of the Bidder, including but not limited to acts of god, or of the public enemy, restraints of a sovereign state, floods, unusual severe weather conditions.

d) **Arbitration:** Any dispute or difference whatsoever arising between the parties out of or relating to the construction, meaning, scope, operation or effect of this contract or the validity or the breach thereof shall be settled by arbitration in accordance with the Rules of Arbitration of the Indian Council of Arbitration and the award made in pursuance thereof shall be binding on the parties. The Arbitration proceeding shall be governed by the Arbitration and Conciliation Act,1996 and the seat of arbitration shall be Haryana.

e) **Jurisdiction of Dispute:** All dispute(s) under this contract shall be subject to the jurisdiction of Punjab and Haryana High Court.

f) **Terms not expressly provided for:** In case this RFP document does not contain a provision or terms for dealing with a situation they may arise during the execution of the works, the relevant provisions contained in the General Financial Rule 2017 or other relevant rule of the Govt. of India shall be followed in such cases and the same will be binding on the Bidder.

17. Special Instructions:

a) In case, the last date of receipt of proposals and/or the day of opening of proposals is declared as a Public Holiday or there is non- functioning of the institute due to any unavoidable reason, the next working day will be treated as the last date of receipt of proposals and/or the day of opening of proposals. The time will remain the same. No separate intimation will be given in this connection.

b) Notification of amendments: As a result of the presentation by the bidders, if the contents of the RFP require any modification, suitable amendment to the RFP document will be issued and the same will form a part of the RFP document. Corrigendum/amendments etc., if any, will be notified through email.

c) The Bidder shall carefully examine and understand the specifications/conditions of the RFP document and if required seek clarifications in writing during the presentation to ensure that they have understood all specifications/conditions of the RFP document. If no such clarifications are sought in writing, it will be taken that the Bidder has read, understood and accepted all the terms, conditions and specifications in the RFP document.

d) The Bidder is required to submit a copy of this RFP document, with all pages signed by the authorized person, to confirm that Bidder has read and understood the conditions

of this RFP document and that the proposal is submitted in full understanding and agreement of the requirements of the institute.

e) The complete proposal submitted by the Bidder should be without alteration or erasures, except those to accord with instructions issued by the institute or as necessary to correct errors made by the Bidder, in which case, such corrections shall be initialled by the person or persons signing the proposal.

f) Wherever a specific form is prescribed in the RFP document, the Bidder shall use the form to provide relevant information. If the form does not provide space for any required information, space at the end of the form or additional sheets shall be used to convey the said information. For all other cases, the Bidder shall utilize a suitable format to provide the required information.

g) The Bidder shall explicitly indicate the non-compliance or deviation of the solution offered in the Proposal to all the terms, clauses, conditions and specifications stipulated in this RFP. If non-compliance or deviation for any term, clause, condition or specification is not explicitly indicated, it will be construed as compliance and if successful in the bidding process, the Bidder is obligated to comply with all the requirements (excluding those non compliances explicitly accepted by the institute in writing) in toto.

h) Successful Bidder shall perform all the obligations specified in accordance with the terms and conditions laid down in the RFP. All details provided by the Bidder should be specific to the requirements specified in this RFP. Detailed clarification may be provided by Bidder, if so desired by the institute. The Bidder shall specify the responsibilities of the institute, if any, separately for the successful implementation of the project.

i) The institute reserves the right to call for any clarifications confined in the broad scope, wherever such a clarification become necessary for proper judgment in evaluation.

j) The Joint Venture/consortium are not allowed to submit Proposals in response to this RFP.

18. Disclaimer:

a) The institute shall not be responsible for any late receipt for any reason whatsoever. The applications received late will not be considered and will be returned unopened to the Bidder.

b) The institute reserves the right;

   i. To relax or waive any of the conditions stipulated in this document as deemed necessary in the best interest of the institute duly informing the stakeholders.

   ii. To include any other item in the Scope of work at any time after consultation with Bidders or otherwise.

   iii. To accept/ reject any or all proposals either in part or in full without assigning any reasons thereof.

   iv. To cancel RFP in part or in full without assigning any reasons thereof.

LETTER OF PROPOSAL SUBMISSION

To,
Executive Director
Translational Health Science and Technology Institute
NCR Biotech Science Cluster, 3rd Milestone,
Faridabad-Gurgaon Expressway, Faridabad

Subject: Letter for Authorized Signatory
Ref: RFP No: THSTI/S&P/RFP/06/25-26

Dear Sir(s):
We, the undersigned, offer to provide the work for 'Optimization of technology for production of Hepatitis E virus-like particle (HEVLP) in 5–10 L scale bioreactor and supply of approximately 10 mg of 90% or more purified HEVLP protein."' in accordance with your RFP referred above. We are hereby submitting our Proposal, which is included in this Technical Proposal.

We hereby declare that all the information and statements made in this Proposal are true and accept that any misinterpretation contained in it may lead to our disqualification.

Our Proposal is binding upon us and subject to the modifications resulting from Technical discussions.

We understand you are not bound to accept any Proposal you receive.

Name of Firm
Authorized Signature [In full and initials]
Name and Title of Signatory
Address

FORMAT FOR TECHNICAL PROPOSAL SUBMISSION

Please provide all the information to fulfil evaluation criteria and for ease of reference. The proposal should be in a Word document. Description should be focused on the project at hand and avoid excessive background information that does not address specific points of the proposed project.

The presentation shall follow a similar format, but can be done with PowerPoint slides. For the presentation, the Bidder should plan the content to stay within the allotted time, while covering the important features of their proposal.

1. Summary of the project

Please provide an overall summary of your ability (financial and infrastructure) and experience to execute the project.

2. Experience

a) Description of prior experience and capabilities in the proposed project domain.
b) Details of products developed. Please provide as much detail and specifics as possible to justify the claims.
c) Commercialization status of previous products.

3. Work plan for executing the project

The work plan must be broken up module wise and align to the scope of work given earlier. All relevant scientific and operational points must be addressed to give a complete view of how the project will be executed, considering scenarios of different situations that may be encountered during execution. The description should be in Word format, but you may use any diagrams, flow charts, pictures, etc. for ease of understanding.
Bidder should include any highlights of technology, unique advantages or experience or any other aspects that favour the Bidder for consideration, in the respective module.

4. Gantt chart of the project

Gantt chart of the project to be provided in MS Excel format. Timeline should be in weeks.

5. Infrastructure and resources

a) Description of the laboratory infrastructure and equipment available.
Note, Work must be carried out in the laboratories and using the equipment as described here.

b) Description of the qualifications, experience and achievements of key personnel including the lead scientist and other team members who will be running the project. The identified lead scientist must operationally lead the project if awarded. Also provide an overall organogram of the key technical personnel involved in the project and their reporting structures.

Note, any change of personnel after award of contract will require consent of the institute. Consent will be given if justified and if the replacement personnel have equivalent experience and expertise.

6. **Project Management and project governance approach.** This will include frequency of meetings, project management structure, escalation matrix and any other details.

Authorization Letter
(To be submitted on Facility's Letter Head)

To,
Executive Director
Translational Health Science and Technology Institute
NCR Biotech Science Cluster, 3rd Milestone,
Faridabad-Gurgaon Expressway, Faridabad

Subject: Letter for Authorized Signatory
Ref: RFP No: THSTI/S&P/RFP/06/25-26

Sir,
This has reference to your above-mentioned RFP for Optimization of technology for production of Hepatitis E virus-like particle (HEVLP) in 5–10 L scale bioreactor and supply of approximately 10 mg of 90% or more purified HEVLP protein.

Mr./Ms./Mrs./Dr ..... is hereby authorized to submit the Proposal document in response to the RFP and participate in the processing on behalf of M/s…… (Laboratory/Facility Name), whose signature is below.

(Specimen Signature of Representative)
Date:
Place:

Yours faithfully,

(Signature of the Authorized signatory)
Name:
Designation:
Seal:
Place:

Undertaking with regard to laboratory facility
(To be submitted on facility's Letter Head)

To,
Executive Director
Translational Health Science and Technology Institute
NCR Biotech Science Cluster, 3rd Milestone,
Faridabad-Gurgaon Expressway, Faridabad

Subject: Undertaking regarding laboratory infrastructure.
Ref: RFP No: THSTI/S&P/RFP/06/25-26

Sir,

It is hereby confirmed and declared that M/s ..... (Laboratory/Facility Name) do have

i. Adequate laboratory infrastructure and

ii. Adequate no. of experienced staff/skilled manpower to undertake Optimization of technology for production of Hepatitis E virus-like particle (HEVLP) in 5–10 L scale bioreactor and supply of approximately 10 mg of 90% or more purified HEVLP protein.

Yours faithfully,

(Signature of the Authorized signatory)
Name:
Designation:
Seal:
Place:

ANNEXURE-II

FORMAT FOR FINANCIAL BID

S. No	Particulars	Amount in Rs
1	Pilot scale optimization of the production pipeline and demonstration of neutralization potential of the antibody induced by the purified protein antigen.	
2	3-5 consistency batch data generation and completion of characterization.	
3	Stability data generation and detailed technical report submission.	
Total		
GST		
Grand Total		

……**End of the Document**……..